Abstract
Purpose:
To compare the rate of intraoperative complications and visual outcomes in patients with neovascular age-related macular degeneration (NvAMD) and control eyes without NvAMD undergoing phacoemulsification.
Setting:
Multicenter study.
Design:
Retrospective, nonrandomized comparative study.
Methods:
Eyes were classified based on the presence or absence of an NvAMD diagnosis. The main outcomes were (1) the rate of intraoperative complications, (2) the logMAR visual acuity (VA) at 4 to 12 weeks postoperatively in both groups, and (3) the reinjection rate of intravitreal antivascular endothelial growth factor after phacoemulsification.
Results:
Preoperative VA was worse in the NvAMD group (0.9 ± 0.5) compared with the reference group (0.6 ± 0.5). We observed no difference in the rate of posterior capsule rupture (PCR) (2.90% vs 2.77%; P = .889), dropped lens fragments (0.46% vs 0.29%; P = .618), or zonular dialysis (0.46% vs 0.58%, P = .749) between the 2 groups. Receiving ≥10 intravitreal injections before cataract surgery predicted the likelihood of PCR with an odds ratio of 2.86 (P = .027). Proportions of eyes achieving a visual gain of ≥0.3 logMAR (∼3 Snellen lines equivalent) was lower in NvAMD eyes (39.2% vs 63.7%; P < .0001). We observed 203 eyes (73%) in the active treatment group and 139 eyes (36%) in the inactive treatment group received >1 intravitreal injection after phacoemulsification (P < .0001).
Conclusions:
The risk for PCR was higher for eyes receiving ≥10 intravitreal injections before phacoemulsification. Only 39% of eyes with NvAMD had visual improvement by ≥3 Snellen lines.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference21 articles.
1. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010;Bloch;Am J Ophthalmol,2012
2. The global burden of cataract;Rao;Curr Opin Ophthalmol,2011
3. Global, regional, national burden and gender disparity of cataract: findings from the Global Burden of Disease Study 2019;Fang;BMC Public Health,2022
4. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment;Vyawahare;Cureus,2022
5. Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: results from the Global Burden of Disease Study 2019;Jiang;Front Public Health,2023